USD 8.79
(-8.53%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.1 Billion USD | -67.17% |
2022 | 2.48 Billion USD | 23.34% |
2021 | 2.01 Billion USD | 916.1% |
2020 | 198.07 Million USD | 57.47% |
2019 | 125.78 Million USD | 0.0% |
2001 | 177.86 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 174.61 Million USD | 0.78% |
2024 Q2 | 175.68 Million USD | 53.11% |
2023 Q3 | 238.69 Million USD | -3.22% |
2023 Q1 | 274.07 Million USD | -9.42% |
2023 FY | 814.87 Million USD | -67.17% |
2023 Q2 | 246.62 Million USD | -10.02% |
2023 Q4 | 173.26 Million USD | -27.41% |
2022 Q3 | 694.76 Million USD | -4.51% |
2022 FY | 2.48 Billion USD | 23.34% |
2022 Q2 | 727.61 Million USD | -3.94% |
2022 Q1 | 757.48 Million USD | -57.12% |
2022 Q4 | 302.57 Million USD | -56.45% |
2021 FY | 2.01 Billion USD | 916.1% |
2021 Q4 | 1.76 Billion USD | 2054.98% |
2021 Q3 | 81.98 Million USD | -5.19% |
2021 Q2 | 86.47 Million USD | 11.56% |
2021 Q1 | 77.51 Million USD | 4.6% |
2020 Q1 | 45.94 Million USD | 0.0% |
2020 FY | 198.07 Million USD | 57.47% |
2020 Q3 | 45.94 Million USD | 18.67% |
2020 Q4 | 74.1 Million USD | 61.28% |
2020 Q2 | 38.71 Million USD | -15.73% |
2019 FY | 125.78 Million USD | 0.0% |
2001 Q1 | 842.92 Million USD | 0.0% |
2001 Q3 | 719.41 Million USD | -9.11% |
2001 FY | 177.86 Million USD | 0.0% |
2001 Q2 | 791.52 Million USD | -6.1% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ADC Therapeutics SA | 233.01 Million USD | -375.669% |
Alto Neuroscience, Inc. | 37.8 Million USD | -2831.524% |
Annovis Bio, Inc. | 45.03 Million USD | -2361.152% |
Biohaven Pharmaceutical Holding Company Ltd. | 436.05 Million USD | -154.186% |
Nuvation Bio Inc. | 99.82 Million USD | -1010.356% |
Nuvation Bio Inc. | 99.82 Million USD | -1010.356% |
Arcus Biosciences, Inc. | 457 Million USD | -142.534% |
Theriva Biologics, Inc. | 21.43 Million USD | -5071.854% |
Zymeworks Inc. | 196.76 Million USD | -463.316% |